Kalpana Patle*, Mithun Bhowmick, Jagdish Rathi
NRI Institute of Pharmaceutical Sciences, Bhopal, India
Diabetes Mellitus is a chronic metabolic disorder characterized by chronic hyperglycemia caused by insulin deficiency, often combined with insulin resistance resulting in the disturbance of carbohydrate, protein and fat metabolism. Anti diabetic drugs which are important for the treatment of hyperglycemic disorders are rapid and almost completely absorbed from the GIT following oral administration, but undergoes extensive first pass metabolism. The oral therapy of anti diabetic drugs also comprises problems of bioavailability fluctuations, severe hypoglycaemia and gastric disturbances. Thus, to develop safe, effective and convenient therapy has became a necessity. Hence, it is required to design a drug delivery system which may deliver anti- diabetic drugs in controlled manner for a prolonged period of time to circumvent the drug related side effects. Hence, it is required to design a drug delivery system which may deliver the drug in controlled manner for a prolonged period of time to circumvent the drug related side effects. Considering all these problems associated with oral administration of anti diabetic drug, attempt has been made to develop transdermal drug delivery system in order to achieve a better release pattern. Thus, Monolithic Matrix-type transdermal systems of Vildagliptin was formulated using polymers Eudragit RSPO and Eudragit RLPO, HPMC and Ethyl Cellulose and characterized for Thickness, Weight variation, Folding endurance, Moisture absorption, Moisture loss, Drug content, Drug–polymer interactions and In- vitro drug release studies.
Keywords: Diabetes Mellitus, Monolithic, Matrix, transdermal, Vildagliptin